2 results
Approved WMORecruiting
To evaluate whether a faecal calprotectin guided strategy of anti-TNF dosing interval lengthening is non-inferior in maintaining remission in patients with IBD compared with an unchanged dosing interval.
Approved WMORecruiting
To assess uptake (visual and quantitative) of 89Zr-ipilimumab in tumor lesions and biodistribution at start of nivolumab/ipilimumab therapy Secondary1. To determine the correlation between tumor targeting of ipilimumab and response to therapy.2. To…